.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Treat-to-target transformed rheumatoid arthritis management by making remission or low disease activity an explicit therapeutic goal rather than accepting persistent symptoms as inevitable. International recommendations emphasize regular disease-activity assessment, timely adjustment of disease-modifying therapy and escalation when the patient is not reaching target. The approach is supported by randomized and observational evidence showing better functional and structural outcomes when disease activity is controlled early and systematically. For general physicians, the message is particularly relevant because RA is not simply a joint disease: cardiovascular risk, infection risk, osteoporosis, fatigue and extra-articular disease all influence long-term outcomes. Methotrexate remains a cornerstone for many patients, while biologic or targeted synthetic DMARDs are added when response is inadequate. Decisions should consider safety factors, vaccination status and comorbidities. The practical strength of treat-to-target is that it turns follow-up into an active control loop—measure, compare with target, modify treatment and reassess—rather than a series of disconnected visits. This strategy fits the conference's emphasis on practical clinical medicine because it connects evidence with a repeatable workflow that can be implemented outside specialist centers.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Treat-to-target transformed rheumatoid arthritis management by making remission or low disease activity an explicit therapeutic goal rather than accepting persistent symptoms as inevitable. International recommendations emphasize regular disease-activity assessment, timely adjustment of disease-modifying therapy and escalation when the patient is not reaching target. The approach is supported by randomized and observational evidence showing better functional and structural outcomes when disease activity is controlled early and systematically. For general physicians, the message is particularly relevant because RA is not simply a joint disease: cardiovascular risk, infection risk, osteoporosis, fatigue and extra-articular disease all influence long-term outcomes. Methotrexate remains a cornerstone for many patients, while biologic or targeted synthetic DMARDs are added when response is inadequate. Decisions should consider safety factors, vaccination status and comorbidities. The practical strength of treat-to-target is that it turns follow-up into an active control loop—measure, compare with target, modify treatment and reassess—rather than a series of disconnected visits. This strategy fits the conference's emphasis on practical clinical medicine because it connects evidence with a repeatable workflow that can be implemented outside specialist centers.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
